Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$17.76 - $31.18 $1.19 Million - $2.09 Million
-67,152 Reduced 89.36%
7,997 $202,000
Q4 2023

Feb 14, 2024

BUY
$11.38 - $50.33 $855,195 - $3.78 Million
75,149 New
75,149 $1.75 Million
Q1 2023

May 15, 2023

SELL
$37.27 - $50.24 $258,840 - $348,916
-6,945 Reduced 25.69%
20,091 $768,000
Q4 2022

Feb 14, 2023

BUY
$33.44 - $54.8 $904,083 - $1.48 Million
27,036 New
27,036 $1.48 Million
Q1 2021

May 17, 2021

SELL
$24.04 - $34.19 $957,152 - $1.36 Million
-39,815 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$25.12 - $29.89 $749,329 - $891,618
29,830 Added 298.75%
39,815 $1.03 Million
Q3 2020

Nov 16, 2020

SELL
$30.79 - $39.92 $157,121 - $203,711
-5,103 Reduced 33.82%
9,985 $307,000
Q2 2020

Aug 14, 2020

SELL
$19.25 - $26.76 $82,967 - $115,335
-4,310 Reduced 22.22%
15,088 $376,000
Q1 2020

May 15, 2020

SELL
$12.8 - $27.05 $500,608 - $1.06 Million
-39,110 Reduced 66.85%
19,398 $411,000
Q4 2019

Feb 14, 2020

BUY
$17.37 - $27.27 $688,442 - $1.08 Million
39,634 Added 209.99%
58,508 $1.3 Million
Q3 2019

Nov 14, 2019

BUY
$16.89 - $29.88 $318,781 - $563,955
18,874 New
18,874 $429,000

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.36B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.